Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding
Author:
Affiliation:
1. Morphotek Inc.; Exton PA USA
Funder
Morphotek Inc
Publisher
Wiley
Subject
Immunology,Immunology and Allergy
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/eji.201847707/fullpdf
Reference38 articles.
1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010
2. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet,2015
3. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion;Hudak;Nat. Chem. Biol.,2014
4. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9;Ohta;Biochem. Biophys. Res. Comm.,2010
5. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse;Vergote;J. Clin. Oncol.,2016
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects;PLOS ONE;2023-05-17
2. Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities;Advanced Science;2023-05-07
3. Recent Advances in Supramolecular-Macrocycle-Based Nanomaterials in Cancer Treatment;Molecules;2023-01-27
4. Block‑Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125‑mediated immunosuppression;Oncology Letters;2021-11-02
5. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3